Selpercatinib for Named Patient Import

Selpercatinib for Indian Patients

Selpercatinib is a recently approved FDA drug which is now commercialized. This medication is recommended in Non-small cell lung cancer, Medullary thyroid cancer and Thyroid cancer management. Developed by Loxo Oncology Inc, this drug is now promoted by Eli Lilly. Globally it is known by its registered brand name - Retevmo.

Selpercatinib or Retevmo in India can only be accessed through legal channels of Import. It is yet to receive the Indian regulatory approvals. Retevmo is commercially supplied as Retevmo 40mg and Retevmo 80mg capsules. Indian Patients who require immediate treatment with Selpercatinib can process a Named Patient Import Permit application. It’s the official way to procure this drug for personal use.

Selpercatinib in India? We can help.

As a patient in India looking for reliable international companies, you will find us the best when it comes to genuineness. Our team carries great experience and track record of assisting Indian Patients. We will support you to complete procedures and also reach out to the reliable global sources. They are duly licensed and have the expertise of managing Import of advanced drugs like Selpercatinib or Retevmo.

Email at nhs@noelbiotech.com or call us on + 91 9677010046 / + 91 9929277766.